Empagliflozin Reduces Liver Fat in Individuals With and Without Diabetes.

Siham AbdelganiAhmed KhattabJohn AdamsGozde BaskoyMarissa BrownGeoff ClarkeOlga LarvenenkoRalph A De Fronzo Muhammad A Abdul-Ghani

Published in: Diabetes care (2024)

Empagliflozin is effective in reducing liver fat content in individuals with and without T2D. The decrease in liver fat content is independent of the decrease in plasma glucose concentration and is strongly related to the decrease in body weight and improvement in insulin sensitivity.

Keyphrases

body weight
adipose tissue
fatty acid
cardiovascular disease
blood glucose
metabolic syndrome
skeletal muscle